中国当代医药
中國噹代醫藥
중국당대의약
PERSON
2015年
17期
64-66
,共3页
长春瑞滨%卡培他滨%乳腺癌%复发%转移%无病生存
長春瑞濱%卡培他濱%乳腺癌%複髮%轉移%無病生存
장춘서빈%잡배타빈%유선암%복발%전이%무병생존
Vinorelbine%Capecitabine%Mammary cancer%Recurrence%Metastasis%Disease free survival
目的：探讨长春瑞滨联合卡培他滨对乳腺癌患者复发转移和无病生存的影响。方法选取本院2006年1月~2010年1月收治的乳腺癌患者50例，患者均给予长春瑞滨及卡培他滨化疗，其中行单纯辅助化疗44例，辅助化疗+内分泌治疗6例。分析患者的近期疗效、中位生存期、不良反应等情况。结果50例患者中，有效率为40.0%，疾病控制率为82.0%；50例患者中二线治疗应用本方案化疗30例，RR为50.0%，三线治疗及之后应用本方案化疗20例，RR为25.0%；随访3~60个月，50例患者中37例死亡，其中7例为PR患者，21例为SD患者，9例为PD患者；3例CR患者获得4年以上无病生存，3例患者2年后复发或出现新病灶，所有患者的中位无进展生存期为10个月(0~60个月)，中位生存期为16个月(3~60个月)；主要不良反应为骨髓抑制，白细胞减少比例为88.0%，同时伴有恶心呕吐、食欲不振等消化道症状。结论长春瑞滨联合卡培他滨治疗乳腺癌的效果确切，不良反应较少，患者耐受性好，可减少复发转移，延长患者的无病生存期。
目的：探討長春瑞濱聯閤卡培他濱對乳腺癌患者複髮轉移和無病生存的影響。方法選取本院2006年1月~2010年1月收治的乳腺癌患者50例，患者均給予長春瑞濱及卡培他濱化療，其中行單純輔助化療44例，輔助化療+內分泌治療6例。分析患者的近期療效、中位生存期、不良反應等情況。結果50例患者中，有效率為40.0%，疾病控製率為82.0%；50例患者中二線治療應用本方案化療30例，RR為50.0%，三線治療及之後應用本方案化療20例，RR為25.0%；隨訪3~60箇月，50例患者中37例死亡，其中7例為PR患者，21例為SD患者，9例為PD患者；3例CR患者穫得4年以上無病生存，3例患者2年後複髮或齣現新病竈，所有患者的中位無進展生存期為10箇月(0~60箇月)，中位生存期為16箇月(3~60箇月)；主要不良反應為骨髓抑製，白細胞減少比例為88.0%，同時伴有噁心嘔吐、食欲不振等消化道癥狀。結論長春瑞濱聯閤卡培他濱治療乳腺癌的效果確切，不良反應較少，患者耐受性好，可減少複髮轉移，延長患者的無病生存期。
목적：탐토장춘서빈연합잡배타빈대유선암환자복발전이화무병생존적영향。방법선취본원2006년1월~2010년1월수치적유선암환자50례，환자균급여장춘서빈급잡배타빈화료，기중행단순보조화료44례，보조화료+내분비치료6례。분석환자적근기료효、중위생존기、불량반응등정황。결과50례환자중，유효솔위40.0%，질병공제솔위82.0%；50례환자중이선치료응용본방안화료30례，RR위50.0%，삼선치료급지후응용본방안화료20례，RR위25.0%；수방3~60개월，50례환자중37례사망，기중7례위PR환자，21례위SD환자，9례위PD환자；3례CR환자획득4년이상무병생존，3례환자2년후복발혹출현신병조，소유환자적중위무진전생존기위10개월(0~60개월)，중위생존기위16개월(3~60개월)；주요불량반응위골수억제，백세포감소비례위88.0%，동시반유악심구토、식욕불진등소화도증상。결론장춘서빈연합잡배타빈치료유선암적효과학절，불량반응교소，환자내수성호，가감소복발전이，연장환자적무병생존기。
Objective To explore the influence of vinorelbine combined with capecitabine on recurrence,metastasis and disease free survival for patients with mammary cancer. Methods 50 patients with mammary cancer treated in our hos-pital from January 2006 to January 2010 were selected.All patients were given chemotherapy of vinorelbine and capecitabine,among them,44 cases were given simple adjuvant chemotherapy,6 cases were given adjuvant chemothera-py+endocrine therapy.The short-term curative effect,median survival time and adverse reaction of the patients were an-alyzed. Results Among 50 patients,the effective rate was 40.0% and disease control rate was 82.0%.This scheme was used for second-line therapy in 30 cases,and RR was 50.0%,while the scheme was used for the third-line treatment or above,and RR was 25.0%;patients were followed-up for 3 to 60 months,37 cases in 50 patients died,among them,7 cas-es were PR,21 cases were SD,and 9 cases were PD;3 CR patients had disease free survival for over 4 years,3 patients relapsed or new focus appeared 2 years later.Median progression-free survival cycle of all patients was 10 months (0-60 months) and median survival cycle was 16 months (3-60 months);main adverse effect included myelosuppression,the proportion of leukopenia was 88.0%,and some concomitant gastrointestinal symptoms,such as nausea,vomiting and loss of appetite and so on. Conclusion The effect of vinorelbine combined with capecitabine in the treatment of mammary cancer has exact curative effect with less adverse reaction,and higher tolerance of patients and it can reduce relapse and metastasis and prolong patients’disease free survival time.
